Navigation Links
Rewiring DNA circuitry could help treat asthma
Date:7/5/2012

Reprogramming asthma-promoting immune cells in mice diminishes airway damage and inflammation, and could potentially lead to new treatments for people with asthma, researchers have found.

The researchers were able to reprogram the asthma-promoting cells (called Th2 (T-helper 2) cells) after identifying an enzyme that modifies the DNA of these cells. The enzyme could be a target for the development of new treatments for chronic inflammatory diseases, in particular allergic asthma, caused by an excess of Th2 cells.

Walter and Eliza Hall Institute researcher Dr Rhys Allan led the research while working at Institut Curie, Paris. The research team from Institut Curie, National Centre for Scientific Research (CNRS), France, National Institute of Health and Medical Research (INSERM), France, and Montpellier Cancer Research Institute published the study today in the journal Nature.

Dr Allan said the research team discovered that the enzyme Suv39h1 could switch off genes to control the function of Th2 cells, which are key to the allergic response.

"Th2 cells have an important function in the immune response, but they also play a significant role in diseases such as allergic asthma," Dr Allan said. "People with asthma have too many Th2 cells, which produce chemical signals that inflame and damage the upper airways. In this study, we discovered that the Suv39h1 enzyme plays a critical role in programming these asthma-promoting cells, making it a potential target for new therapies to treat asthma."

More than two million Australians have asthma approximately one in 10 people and the disease is even more common among Indigenous Australians. The prevalence of asthma in children in Australia is among the highest in the world. Dr Allan said the Suv39h1 enzyme was part of the 'epigenetic circuitry' of Th2 cells.

"Epigenetics refers to changes or modifications in the DNA that alter how genes are switched on and off, without changing the fundamental DNA sequence. Suv39h1 effectively 'tags' the DNA to tell the cells which genes they need to switch on or off to promote an allergic response."

Using agents that inhibit Suv39h1 could destabilise Th2 cells in people who have an excess of these asthma-promoting cells so they no longer cause inflammation, Dr Allan said.

"We had the idea that erasing these epigenetic tags could 'short-circuit' the asthma-promoting Th2 cells and diminish the inflammatory immune response. And, in fact, in mouse models of allergic asthma, blocking this pathway with an inhibitory compound did reduce allergy-related airway damage. Ultimately, our results have identified a potential target for therapeutic intervention in asthma and potentially other Th2-mediated inflammatory diseases, which could improve outcomes for patients," Dr Allan said.

Dr Allan is continuing to study the epigenetic circuitry of asthma-promoting immune cells in the institute's Molecular Immunology division, with funding from the National Health and Medical Research Council of Australia (NHMRC).


'/>"/>

Contact: Liz Williams
williams@wehi.edu.au
61-405-279-095
Walter and Eliza Hall Institute
Source:Eurekalert

Related medicine news :

1. Charting autisms neural circuitry
2. A better way to test new treatments? Approach could help patients and give useful results
3. The US Drug Watchdog Now Warns Time Could Run Out to Get Women Yaz or Yasmin Birth Control Pill Users Identified if they Suffered a Heart Attack Stroke or a Embolism
4. Dr. Davis Announces Some Diagnoses of ADHD May be Misinterpreted Visual Problems: Could Be Treated with Vision Therapy
5. New technique could reduce number of animals needed to test chemical safety
6. The US Drug Watchdog Now Offers To Help All Recipients Of Recalled DePuy ASR Hip Implant Get To The Best Attorneys Because Time Could Run Out To Get Them Identified
7. Menopausal women could work out their hot flashes
8. EVINCI results could lead to 75 percent reduction of invasive procedures for patients with suspected CAD
9. Victim’s Rights to Recover for Actos Bladder Cancer Could Expire Soon
10. Delaying ADHD Meds Could Hurt Kids Math Scores
11. Could Fertility Drugs Make Kids Shorter?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... ... According to recent statistics, there are nearly half a million physical ... Each physical therapy professional and every clinic has a duty to perform at the ... a competitive industry is also essential. The solution that many physical therapy leaders turn ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... FDAI, DAHC, CDC, has joined the Fire Door Solutions’ team. Keith will ... fire door and frame in-field re-labeling. He will be instrumental in developing ...
(Date:5/31/2016)... ... ... More than 80 representatives of the Hepatitis B Foundation , Hepatitis ... an event on National Hepatitis Testing Day outside of Philadelphia City Hall to raise ... of liver cancer. , Foundation leaders and the citywide coalition they created, Hep B ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... Healthconnect’s (Healthconnect) regional health information exchange, which enables physicians at SJMC’s two hospital ... patients from other participating organizations in the exchange. SJMC’s membership in the health ...
(Date:5/31/2016)... Beach, Florida (PRWEB) , ... May 31, 2016 ... ... to Jay Butch of CertainTeed Corporation, he knew it was something that contractors ... as state-of-the-art and cutting-edge as it gets,” says Butch, CertainTeed’s Director of Contractor ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... ORANGE COUNTY, Calif. , May 27, 2016  A new study highlights the ... study conducted by the  Journal of the American College of Radiology , a majority ... particular procedures. Photo - http://photos.prnewswire.com/prnh/20160527/373022 ... ... Medical Diagnostic ...
(Date:5/27/2016)... , May 27, 2016 ... instances of hypertension is driving ambulatory blood pressure monitoring ... their elasticity and their ability to respond to different ... This condition can lead to various cardiovascular disorders such ... vascular disease. These diseases are growing in prevalence each ...
(Date:5/27/2016)... TEL-AVIV, Israel , May 27, 2016 /PRNewswire/ ... KTOV), an innovative biopharmaceutical company focused on late-stage ... by Dexcel Pharma of pivotal batches ... Food and Drug Administration (FDA). This follows Kitov,s ... pivotal Phase III trial successfully met its primary ...
Breaking Medicine Technology: